GoAI
Get started
Benitec Biopharma Inc. logo

Benitec Biopharma Inc.

BNTC

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$13.48

+$0.47 · +3.61%

Aug 21, 4:00 PM ET

BNTC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

54

Neutral

Sentiment

49

Mixed

Risk resilience

53

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jerel A. Banks
Listed since
Jun 24, 2014
Employees
19

Market position

Day range

Current $13.48

52-week range

Current $13.48

Open
$13.14
Previous close
$13.01
Volume
160.14K
1.27× average
Average volume
126.21K
Average daily volume
Market cap
463.1M USD
Beta
0.26
Market reference 1
50-day average
$12.5638
+7.29% above average
200-day average
$12.149
+10.96% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-12.14×
P/B (TTM)
3.63×
P/S (TTM)
832.91×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-14.21%
Operating margin
-9701.08%
Net margin
-8792.09%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2718%-7755%-18228%-28701%Gross margin, FY2021: -108.47%Gross margin, FY2022: 87.67%Gross margin, FY2023: 100.00%Operating margin, FY2021: -23044.07%Operating margin, FY2022: -24457.53%Operating margin, FY2023: -25441.33%Net margin, FY2021: -23528.81%Net margin, FY2022: -24942.47%Net margin, FY2023: -26082.67%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 -108.47%. Gross margin FY2022 87.67%. Gross margin FY2023 100.00%. Operating margin FY2021 -23044.07%. Operating margin FY2022 -24457.53%. Operating margin FY2023 -25441.33%. Net margin FY2021 -23528.81%. Net margin FY2022 -24942.47%. Net margin FY2023 -26082.67%.

Income trends

Revenue

75K USD+2.74%

Operating income

−41.77M USD-85.70%

Net income

−37.92M USD-74.32%
Income trends across reported periods4.26M USD−12.48M USD−29.21M USD−45.95M USDRevenue, FY2021: 59K USDRevenue, FY2022: 73K USDRevenue, FY2023: 75K USDOperating income, FY2021: −13.6M USDOperating income, FY2022: −17.85M USDOperating income, FY2023: −19.08M USDOperating income, FY2024: −22.49M USDOperating income, FY2025: −41.77M USDNet income, FY2021: −13.88M USDNet income, FY2022: −18.21M USDNet income, FY2023: −19.56M USDNet income, FY2024: −21.75M USDNet income, FY2025: −37.92M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 59K USD. Revenue FY2022 73K USD. Revenue FY2023 75K USD. Operating income FY2021 −13.6M USD. Operating income FY2022 −17.85M USD. Operating income FY2023 −19.08M USD. Operating income FY2024 −22.49M USD. Operating income FY2025 −41.77M USD. Net income FY2021 −13.88M USD. Net income FY2022 −18.21M USD. Net income FY2023 −19.56M USD. Net income FY2024 −21.75M USD. Net income FY2025 −37.92M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue——75K USD73K USD59K USD
Cost of goods sold396K USD343K USD—9K USD123K USD
Gross profit−396K USD−343K USD75K USD64K USD−64K USD
Research and development18.33M USD15.61M USD12.77M USD11.27M USD7.02M USD
Selling, general, and administrative23.43M USD6.99M USD6.38M USD6.65M USD6.51M USD
Operating expenses41.77M USD22.49M USD19.16M USD17.92M USD13.53M USD
Interest income—904K USD———
Interest expense−3.29M USD—33K USD32K USD6K USD
Depreciation and amortization396K USD343K USD381K USD392K USD424K USD
Operating income−41.77M USD−22.49M USD−19.08M USD−17.85M USD−13.6M USD
Net income−37.92M USD−21.75M USD−19.56M USD−18.21M USD−13.88M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-109.32%
11 comparable reports
Latest EPS result
-0.24
Estimate -0.27 · Beat by 11.11%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.19-0.48-0.77-1.06Q4 '24BeatQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26Estimate
Q4 2024, reported Nov 14, 2024: actual -0.48, estimate -0.55, surprise +12.73%, Beat. Q1 2025, reported Feb 14, 2025: actual -0.36, estimate -1, surprise +64.00%, Beat. Q2 2025, reported May 14, 2025: actual -0.24, estimate -0.36, surprise +33.33%, Beat. Q3 2025, reported Sep 22, 2025: actual -0.42, estimate -0.28, surprise -50.00%, Miss. Q4 2025, reported Nov 14, 2025: actual -0.22, estimate -0.35, surprise +37.14%, Beat. Q1 2026, reported Feb 12, 2026: actual -0.26, estimate -0.23, surprise -13.04%, Miss. Q2 2026, reported May 14, 2026: actual -0.24, estimate -0.27, surprise +11.11%, Beat. Q3 2026, reported Sep 28, 2026: actual —, estimate -0.26, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates4.91M3.15M1.39M-370.48KQ3 '24No estimateQ3 '25No estimateQ2 '26Estimate
Q3 2024, reported Sep 26, 2024: actual -6K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Sep 22, 2025: actual 556K USD, estimate —, surprise —, Comparison unavailable. Q2 2026, reported May 14, 2026: actual —, estimate 4.55M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$20.50

52.08% upside
Past 12 months12-month forecastHigh $25.00Average $20.50Low $16.00

Rating distribution

7 ratings
Strong buy00%
Buy686%
Hold114%
Sell00%
Strong sell00%

Corporate actions

Corporate action history

Dividend

Ex-dividend Jun 1, 2018

$0.003

Irregular

Record Jun 4, 2018 · Payment Jun 8, 2018

BNTC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BNTC

Funds reporting this stock among their holdings, ordered by reported position size.

Simplify Health Care ETF logoSimplify Health Care ETFPINK
Market value
14.18M
Weight
3.72%
AUM
380.8M USD
Expense ratio
0.51%
Price / 1D
$40.21+1.16%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
7.61M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
6.83M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.34M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
2.43M
Weight
0.02%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.4M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
959.33K
Weight
0.06%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Global X - Genomics & Biotechnology ETF logoGlobal X - Genomics & Biotechnology ETFGNOM
Market value
315.22K
Weight
0.33%
AUM
94.83M USD
Expense ratio
0.50%
Price / 1D
$66.77+2.88%

Continue in GoAI

Research BNTC

research.disclaimer